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The fast neutron therapy programme 
for patients in South Africa should 
come to an end  
To the Editor: Neutron therapy for tumours was introduced globally 
and in South Africa to evaluate the possible improvement of results 
obtained with conventional photon radiotherapy.1,2 This was based on 
the radiobiological finding that neutron irradiation is more effective 
in killing all cells, including poorly oxygenated tumour cells which 
are relatively resistant to conventional photon radiation.
Neutron therapy, however, also causes an increase in late normal 
tissue toxicity, in part because cells are not able to repair any sub-
lethal radiation damage sustained during irradiation. These late 
effects are a decrease in functional parenchymal cells, increased 
fibrosis and a reduced vascular supply and can occur in all irradiated 
tissue, for example skin, soft tissues, bowel and brain. This late 
toxicity is progressive with time as the damaged cells produce 
cytokines which promote fibrosis.  
Clinical studies of neutron therapy in the 1950s showed an increase 
in severe late toxicity. Clinical studies during the 1980s and 1990s, 
based on a better understanding of the radiobiology and using more 
refined techniques, unfortunately again showed an increase in late 
normal tissue toxicity.  
There was an overwhelming consensus in the radiation oncology 
community that it was time to focus on other methods to improve 
results.1,2 Neutron therapy sites were shut down in England, Europe, 
Canada and the USA, except for two USA-based sites. However, 
neutron therapy continues to be offered in South Africa, despite the 
referral of decreasing numbers of patients.  
Those who favour this continuation of the neutron therapy 
programme in South Africa argue that it is useful in some specific 
sites, specifically salivary gland tumours and sarcomas. However, 
this is not supported by the evidence from phase III studies. 
Among patients with inoperable salivary gland tumours, a phase III 
randomised trial of only 32 patients compared neutron therapy with 
photon therapy.3 The study showed an increase in local control, but 
no increase in survival and also increased complications with neutron 
therapy. For patients with sarcomas, a phase III trial of postoperative 
radiation was halted after 14 patients were accrued because of severe 
late normal tissue toxicity in patients treated with neutron therapy.4
Neutron therapy advocates also argue for its use in patients with 
advanced cancer on the premise that the patients will die before they 
have the opportunity to develop complications. This is an extremely 
expensive form of palliative therapy that could also be done through 
other means and is not the forward-looking perspective associated 
with clinical research.  
Considerable progress towards improving the local control of 
tumours been made with other approaches. Photon radiation may 
be given concurrently with systemic chemotherapy or biological 
therapies and this is now established practice in many diseases, e.g. 
cancer of the cervix, lung and rectum. This does not cause an increase 
in late toxicity, although it may be associated with an increase in acute 
toxicity, which can be actively managed and also minimised through 
careful planning of radiation administration. Proton particle therapy 
is also effective and safe and may be particularly useful in paediatric 
patients.  
The strong negative view of the radiation oncology research 
community towards neutron therapy is reflected in the almost 
complete absence of any publications in peer-reviewed journals on 
neutron therapy since 2000.  
The proven toxicity of neutron therapy and the availability of other 
treatment approaches, indicates that the continuation of neutron 
therapy in South Africa is not justified in terms of patient care or 
clinical research, as well as our need to be fiscally responsible. 
Raymond P Abratt
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